Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432651 · ClinicalTrials.gov registry record · Phase 1
Xanthohumol and Prevention of DNA Damage
A Phase 1 study, sponsored by Oregon State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02432651: Completed Phase 1 study, sponsored by Oregon State University.
NCT02432651 is a Phase 1 study that has completed, run by Oregon State University. The registered enrollment target is 64 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02432651, a Phase 1 study, has completed, sponsored by Oregon State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn if and in what amount a compound from hops, called xanthohumol (ZAN-tho-HUE-mol), prevents damage to DNA and oxidative stress. The human body is constantly exposed to oxidative stress from environmental compounds (e.g. air pollution) which may cause damage to DNA. The human body can repair some DNA damage, but too much DNA damage is harmful and may lead to cancer. Research done at OSU and around the world has shown that xanthohumol can stop or slow processes that lead to cancer.
Primary Outcome
Plasma and urine levels of 8-oxo-dG will be measured at the beginning and end of each 3-week cycle. DNA strand breaks in blood cells and plasma levels of reduced and oxidized glutathione will be measured at the beginning and end of each 3-week cycle. Between the two cycles, there will be a 3-week washout. One cycle is XN treatment, and one cycle is the placebo.
Interventions
- DRUG Placebo
- DRUG 6 mg xanthohumol per day
- DRUG 12 mg xanthohumol per day
- DRUG 24 mg xanthohumol per day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
What the finished NCT02432651 record still lists
NCT02432651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02432651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02432651 about?
NCT02432651 is a clinical study titled "Xanthohumol and Prevention of DNA Damage". The purpose of this research study is to learn if and in what amount a compound from hops, called xanthohumol (ZAN-tho-HUE-mol), prevents damage to DNA and oxidative stress. The human body is constantly exposed to oxidative stress from environmental compounds (e.g. air pollution) which may cause dam...
What is the current status of trial NCT02432651?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2015-03. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02432651?
The interventions under investigation include: Placebo (DRUG), 6 mg xanthohumol per day (DRUG), 12 mg xanthohumol per day (DRUG), 24 mg xanthohumol per day (DRUG).
Who is sponsoring clinical trial NCT02432651?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02432651's enrollment target sits among peer trials
64 808th of 2000 higher than 1,181 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia